Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FMO-guided design of darunavir analogs as HIV-1 protease inhibitors.

Scientific reports - 13 Feb 2024

Chuntakaruk Hathaichanok, Hengphasatporn Kowit, Shigeta Yasuteru, Aonbangkhen Chanat, Lee Vannajan Sanghiran, Khotavivattana Tanatorn, Rungrotmongkol Thanyada, Hannongbua Supot

Abstract excerpt

The prevalence of HIV-1 infection continues to pose a significant global public health issue, highlighting the need for antiretroviral drugs that target viral proteins to reduce viral replication. One such target is HIV-1 protease (PR), responsible for cleaving viral polyproteins, leading to the maturation of viral proteins. While darunavir (DRV) is a potent HIV-1 PR inhibitor, drug resistance can arise due to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Molecular Docking Simulation

Share to Sulfonamides

Share to Viral Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 38351065
DOI: 10.1038/s41598-024-53940-1
PMCID: PMC10864397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FMO-guided design of darunavir analogs as HIV-1 protease inhibitors.PMID 38351065Read ↗

Design of novel HIV-1 protease inhibitors with favorable oral properties using a virtual screening and lead optimization approachSemantic proximity Read ↗

Computer-Aided Algorithmic Approaches to Drug Development for Multi-Mutant HIV-1 Reverse Transcriptase.Semantic proximity Read ↗

An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV‐1 protease variantsSemantic proximity Read ↗

Challenges and approaches in the discovery of human immunodeficiency virus type‐1 non‐nucleoside reverse transcriptase inhibitorsSemantic proximity Read ↗

Towards the de Novo Design of HIV-1 Protease Inhibitors Based on Natural ProductsSemantic proximity Read ↗

Fragment-based Drug Designing to Develop New Hits Against Multiple Receptors of CoronavirusSemantic proximity Read ↗

Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main proteaseSemantic proximity Read ↗

Special Features of COVID-19 in the FMODB: Fragment Molecular Orbital Calculations and Interaction Energy Analysis of SARS-CoV-2-Related ProteinsSemantic proximity Read ↗

Multiple Molecular Dynamics Simulations and Free-Energy Predictions Uncover the Susceptibility of Variants of HIV-1 Protease against Inhibitors Darunavir and KNI-1657.Semantic proximity Read ↗

Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach.Semantic proximity Read ↗

Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main ProteaseSemantic proximity Read ↗

Evaluating the potency of HIV-1 protease drugs to combat resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.